Use of atorvastatin to inhibit hypoxia-induced myocardin expression

European Journal of Clinical Investigation

Volumn 42, Issue 5, 2012, Pages 564-571

  Chiu, Chiung Zuan ^a,b,c   Wang, Bao Wei ^c   Shyu, Kou Gi ^a,c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cardiomyocyte hypertrophy; Reactive oxygen species; Statins; Transcription

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACETYLCYSTEINE; ATORVASTATIN; LUCIFERASE; MYOCARDIN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL MODEL; ARTICLE; CARDIOMYOCYTE HYPERTROPHY; CELL HYPOXIA; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG USE; ENZYME ASSAY; GEL MOBILITY SHIFT ASSAY; HEART MUSCLE CELL; MUSCLE HYPERTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RAT;

ANIMALS; ANIMALS, NEWBORN; ANOXIA; BLOTTING, WESTERN; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY; MYOCYTES, CARDIAC; NUCLEAR PROTEINS; PYRROLES; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS;

EID: 84859717095     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02628.x     Document Type: Article

References (37)

1. Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol 2003;35:577-93.
2. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, Small E et al. Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor. Cell 2001;105:851-62.
3. Zhang X, Azhar G, Zhong Y, Wei JY. Identification of a novel serum response factor cofactor in cardiac gene regulation. J Biol Chem 2004;279:55626-32.
4. Deindl E. Arteriogenesis: focus on signal transduction cascades and transcription factors. Thromb Haemost 2007;98:940-3.
5. Inamoto S, Hayashi T, Tazawa N, Mori T, Yamashita C, Nakano D et al. Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. Circ J 2006;70:787-92.
6. Seta KA, Millhorn DE. Functional genomics approach to hypoxia signaling. J Appl Physiol 2004;96:765-73.
7. Wen JK, Han M. Myocardin. A novel potentiator of SRF-mediated transcription in cardiac muscle. Mol Cell 2002; 8: 1-2.
8. Firulli AB. Another hat for myocardin. J Mol Cell Cardiol 2002;34:1293-6.
9. Parmacek MS. Myocardin-related transcription factors: critical coactivators regulating cardiovascular development and adaptation. Circ Res 2007;100:633-44.
10. Miano JM. Channeling to myocardin. Circ Res 2004;95:340-2.
11. Reynolds PR, Mucenski ML, Le Cras TD, Nichols WC, Whitsett JA. Midkine is regulated by hypoxia and causes pulmonary vascular remodeling. J Biol Chem. 2004;279:37124-32.
12. Kuwahara K, Kinoshita H, Kuwabara Y, Nakagawa Y, Usami S, Minami T et al. Myocardin-related transcription factor A is a common mediator of mechanical stress- and neurohumoral stimulation-induced cardiac hypertrophic signaling leading to activation of brain natriuretic peptide gene expression. Mol Cell Biol 2010;30:4134-48.
13. Chiu CZ, Wang BW, Chung TH, Shyu KG. Angiotensin II and ERK pathway mediate the induction of myocardin by hypoxia in cultured rat neonatal cardiomyocytes. Clin Sci 2010;109:273-82.
14. Yamashita C, Hayashi T, Mori T, Tazawa N, Kwak CJ, Nakano D et al. Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice. Hypertens Res 2007;30:1219-30.
15. Yoshida T, Hoofnagle MH, Owens GK. Myocardin and Prx1 contribute to angiotensin II-induced expression of smooth muscle α-actin. Circ Res 2004;94:1075-82.
16. Sadoshima J, Malhotra R, Izumo S. The role of the cardiac renin-angiotensin system in load-induced cardiac hypertrophy. J Card Fail 1996;2:S1-6.
17. Rikitake Y, Hirata K. Inhibition of RhoA or Rac1? Mechanisms of cholesterol-independent beneficial effects of statins Circ J 2009;73:231-2.
18. Ye Y, Hu SJ, Li L. Inhibition of farnesyl pyrophosphate synthase prevents angiotensin II-induced hypertrophic responses in rat neonatal cardiomyocytes: involvement of the RhoA/Rho kinase pathway. FEBS Lett 2009;583:2997-3003.
19. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A et al. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal regulated kinase-serum response factor signaling pathway. Clin Exp Pharmacol Physiol 2006;33:1164-71.
20. Senthil V, Chen SN, Tsybouleva N, Halder T, Nagueh SF, Willerson JT et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2005;97:285-92.
21. Adam O, Laufs U. Antioxidative effects of statins. Arch Toxicol 2008;82:885-92.
22. Shyu KG, Chen CC, Wang BW, Kuan P. Angiotensin II receptor antagonist blocks the expression of connexin 43 induced by cyclical mechanical stretch in cultured neonatal rat cardiac myocytes. J Mol Cell Cardiol 2001;33:691-8.
23. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006;98:730-42.
24. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW et al. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept 2004;120:5-13.
25. Torrado M, Lopez E, Centeno A, Medrano C, Castro-Beiras A, Mikhailov AT. Myocardin mRNA is augmented in the failing myocardium: expression profiling in the porcine model and human dilated cardiomyopathy. J Mol Med 2008;81:566-77.
26. Pijnappels DA, Tuyn J, Vries AF, Grauss RW, Laarse A, Ypey DL et al. Resynchronization of separated rat cardiomyocyte fields with genetically modified human ventricular scar fibroblasts. Circulation 2007;116:2018-28.
27. Tuyn J, Pijnappels DA, Vries AF, Vries I, Dijke IV, Knan-Shanzer S et al. Fibroblasts from human postmyocardial infarction scars acquire properties of cardiomyocytes after transduction with a recombinant myocardin gene. FASEB J 2007;21:3369-79.
28. Xing W, Zhang TC, Cao D, Wang Z, Antos CL, Li S et al. Myocardin induces cardiomyocyte hypertrophy. Circ Res 2006;98:1089-97.
29. Hakoshima T, Shimizu T, Maesaki R. Structural basis of the Rho GTPase signaling. J Biochem J (Tokyo) 2003;134:327-31.
30. Hofer F. Activated Ras interacts with the Rac1 guanine nucleotide dissociation stimulator. Proc Natl Acad Sci U S A 1994;91:11089-93.
31. Schiller MR. Coupling receptor tyrosine kinases to Rho GTPases-GEFs: what's the link. Cell Signal 2006;18:1834-43.
32. Sagara Y, Hirooka Y, Nozoe M, Ito K, Kimura Y, Sunagawa K. Pressor response induced by central angiotensin II is mediated by activation of Rho/Rho-kinase pathway via AT1 receptors. J Hypertens 2007;25:399-406.
33. Kimura K, Eguchi S. Angiotensin II type-1 receptor regulates RhoA and Rho-kinase/ROCK activation via multiple mechanisms. Am J Physiol Cell Physiol 2009;297:C1059-61.
34. Nohria A, Prsic A, Liu PY, Okamoto R, Creager MA, Selwyn A et al. Statins inhibit Rho kinase activity in patients with atherosclerosis. Atherosclerosis 2009;205:517-21.
35. Hill CS, Wynne J, Treisman R. The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. Cell 1995;81:1159-70.
36. Gineitis D, Treisman R. Differential usage of signal transduction pathways defines two types of serum response factor target gene. J Biol Chem 2001;276:24531-9.
37. Lui HW, Halayko AJ, Fernandes DJ, Harmon GS, McCauley JA, Kocieniewski P et al. The RhoA Rho kinase pathway regulates nuclear localization of serum response factor. Am J Respir Cell Mol Biol 2003;29:39-47.